- Home
- CRVS vs NPCT Comparison
CRVS vs NPCT Comparison
Compare CRVS & NPCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRVS
- NPCT
- Stock Information
- Founded
- CRVS 2014
- NPCT 2020
- Country
- CRVS United States
- NPCT United States
- Employees
- CRVS N/A
- NPCT N/A
- Industry
- CRVS Biotechnology: Pharmaceutical Preparations
- NPCT Investment Managers
- Sector
- CRVS Health Care
- NPCT Finance
- Exchange
- CRVS Nasdaq
- NPCT Nasdaq
- Market Cap
- CRVS 305.4M
- NPCT 316.6M
- IPO Year
- CRVS 2016
- NPCT N/A
- Fundamental
- Price
- CRVS $4.11
- NPCT $11.17
- Analyst Decision
- CRVS Strong Buy
- NPCT
- Analyst Count
- CRVS 4
- NPCT 0
- Target Price
- CRVS $15.00
- NPCT N/A
- AVG Volume (30 Days)
- CRVS 1.2M
- NPCT 107.1K
- Earning Date
- CRVS 08-05-2025
- NPCT 01-01-0001
- Dividend Yield
- CRVS N/A
- NPCT 9.82%
- EPS Growth
- CRVS N/A
- NPCT N/A
- EPS
- CRVS N/A
- NPCT N/A
- Revenue
- CRVS N/A
- NPCT N/A
- Revenue This Year
- CRVS N/A
- NPCT N/A
- Revenue Next Year
- CRVS N/A
- NPCT N/A
- P/E Ratio
- CRVS N/A
- NPCT N/A
- Revenue Growth
- CRVS N/A
- NPCT N/A
- 52 Week Low
- CRVS $1.78
- NPCT $8.58
- 52 Week High
- CRVS $10.00
- NPCT $10.63
- Technical
- Relative Strength Index (RSI)
- CRVS 53.94
- NPCT 64.17
- Support Level
- CRVS $3.79
- NPCT $10.55
- Resistance Level
- CRVS $4.31
- NPCT $11.29
- Average True Range (ATR)
- CRVS 0.29
- NPCT 0.11
- MACD
- CRVS 0.00
- NPCT 0.00
- Stochastic Oscillator
- CRVS 72.64
- NPCT 74.92
About CRVS Corvus Pharmaceuticals Inc.
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).
About NPCT Nuveen Core Plus Impact Fund of Beneficial Interest
Nuveen Core Plus Impact Fund is an organized, diversified, closed-end management investment company. The Fund's investment objective is to seek total return through high current income and capital appreciation, while giving special consideration to certain impact and environmental, social and governance criteria.